EANM指南:2-[18F]FDG PET/CT在卵巢癌诊断、分期、预后价值、疗效评估及再分期中的作用,获美国核医学学会(ACNM)、核医学与分子影像学会(SNMMI)及国际原子能机构(IAEA)认可
该指南由EANM制定,汇总了2-[18F]FDG PET/CT在卵巢癌各疾病阶段的证据等级和推荐等级。文献证据显示其在原发灶检测、疾病分期、预后判断尤其是复发检测方面有效,而在疗效评估方面证据有限。
要点
- 2-[18F]FDG PET/CT在卵巢癌复发检测方面证据充分,指南给出相应推荐等级。
- 原发灶检测、分期和预后判断方面文献显示有效,指南给出证据等级与推荐等级。
- 疗效评估方面证据有限,指南对此作出相应说明。
核心结论
- 该指南总结了2-[18F]FDG PET/CT在卵巢癌各疾病阶段的证据等级和推荐等级,文献证据显示其在原发灶检测、疾病分期、预后判断尤其是复发检测方面有效,而疗效评估方面证据有限。
研究设计与样本
- 欧洲核医学协会(EANM)制定的指南,获美国核医学学会(ACNM)、核医学与分子影像学会(SNMMI)及国际原子能机构(IAEA)认可,汇总文献证据等级与推荐等级。
关键影像表现/征象
- 卵巢癌转移途径包括腹膜连续性播散、淋巴引流播散及血行播散,其中血行播散在该病中重要性较低。
- 放射学影像(超声、CT、MRI)是支持治疗决策的主要影像技术,CT被认为是术前评估和分期的最佳可用技术。
临床应用与阅片要点
- 2-[18F]FDG PET/CT在原发灶检测、疾病分期和预后判断方面文献显示有效。
- 2-[18F]FDG PET/CT尤其适用于复发检测。
- 2-[18F]FDG PET/CT用于疗效评估时证据有限。
局限性
- 2-[18F]FDG PET/CT用于疗效评估时证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
In most patients with ovarian carcinoma, the diagnosis is reached when the disease is long past the initial stages, presenting already an advanced stage, and they usually have a very bad prognosis. Cytoreductive or debulking surgical procedures, platinum-based chemotherapy and targeted agents are key therapeutic elements. However, around 7 out of 10 patients present recurrent disease within 36 months from the initial diagnosis. The metastatic spread in ovarian cancer follows three pathways: contiguous dissemination across the peritoneum, dissemination through the lymphatic drainage and, although less importantly in this case, through the bloodstream. Radiological imaging, including ultrasound, CT and MRI, are the main imaging techniques in which management decisions are supported, CT being considered the best available technique for presurgical evaluation and staging purposes. Regarding 2-[18F]FDG PET/CT, the evidence available in the literature demonstrates efficacy in primary detection, disease staging and establishing the prognosis and especially for relapse detection. There is limited evidence when considering the evaluation of therapeutic response. This guideline summarizes the level of evidence and grade of recommendation for the clinical indications of 2-[18F]FDG PET/CT in each disease stage of ovarian carcinoma.
引用
- Delgado Bolton RC, Aide N, Colletti PM, et al. EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging. 2021. PMID: 34215923. doi:10.1007/s00259-021-05450-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。